$1.26
3.17%
Downside
Day's Volatility :3.18%
Upside
0.01%
10.32%
Downside
52 Weeks Volatility :57.68%
Upside
52.81%
Period | Dyadic International Inc | Index (Russel 2000) |
---|---|---|
3 Months | -37.62% | 0.0% |
6 Months | -9.35% | 0.0% |
1 Year | -31.15% | 0.0% |
3 Years | -79.0% | -22.3% |
Market Capitalization | 38.7M |
Book Value | $0.11 |
Earnings Per Share (EPS) | -0.27 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -528.5% |
Return On Assets TTM | -46.28% |
Return On Equity TTM | -127.38% |
Revenue TTM | 1.8M |
Revenue Per Share TTM | 0.06 |
Quarterly Revenue Growth YOY | -53.900000000000006% |
Gross Profit TTM | 807.1K |
Diluted Eps TTM | -0.27 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.26 |
EPS Estimate Next Year | -0.21 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 376.19%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 1.3M | ↑ 70.81% |
Net Income | -5.7M | ↑ 166.49% |
Net Profit Margin | -439.36% | ↓ 157.75% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.7M | ↑ 29.77% |
Net Income | -8.3M | ↑ 45.96% |
Net Profit Margin | -494.21% | ↓ 54.85% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.6M | ↓ 4.71% |
Net Income | -9.3M | ↑ 12.24% |
Net Profit Margin | -582.13% | ↓ 87.92% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.4M | ↑ 50.06% |
Net Income | -12.9M | ↑ 38.57% |
Net Profit Margin | -537.54% | ↑ 44.59% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.9M | ↑ 21.9% |
Net Income | -9.4M | ↓ 27.48% |
Net Profit Margin | -319.79% | ↑ 217.75% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.9M | ↓ 1.07% |
Net Income | -6.8M | ↓ 27.48% |
Net Profit Margin | -234.42% | ↑ 85.37% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 978.1K | ↑ 31.51% |
Net Income | 137.6K | ↓ 106.64% |
Net Profit Margin | 14.07% | ↑ 292.69% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 837.2K | ↓ 14.41% |
Net Income | -2.2M | ↓ 1664.58% |
Net Profit Margin | -257.17% | ↓ 271.24% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 397.1K | ↓ 52.57% |
Net Income | -1.6M | ↓ 25.02% |
Net Profit Margin | -406.55% | ↓ 149.38% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 686.5K | ↑ 72.9% |
Net Income | -2.1M | ↑ 28.34% |
Net Profit Margin | -301.78% | ↑ 104.77% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 334.6K | ↓ 51.26% |
Net Income | -2.0M | ↓ 3.0% |
Net Profit Margin | -600.57% | ↓ 298.79% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 385.9K | ↑ 15.32% |
Net Income | -2.0M | ↑ 1.77% |
Net Profit Margin | -529.99% | ↑ 70.58% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 43.3M | ↓ 14.67% |
Total Liabilities | 849.6K | ↑ 10.5% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 37.5M | ↓ 13.51% |
Total Liabilities | 1.6M | ↑ 86.91% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 30.1M | ↓ 19.71% |
Total Liabilities | 1.6M | ↑ 2.38% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 21.3M | ↓ 29.17% |
Total Liabilities | 2.9M | ↑ 78.9% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 13.7M | ↓ 35.62% |
Total Liabilities | 2.6M | ↓ 9.75% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 8.2M | ↓ 40.06% |
Total Liabilities | 2.3M | ↓ 10.84% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 12.8M | ↓ 6.57% |
Total Liabilities | 2.0M | ↓ 23.53% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 11.1M | ↓ 13.56% |
Total Liabilities | 2.1M | ↑ 4.07% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 9.3M | ↓ 16.42% |
Total Liabilities | 1.6M | ↓ 23.27% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 8.2M | ↓ 11.2% |
Total Liabilities | 2.3M | ↑ 46.01% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 12.7M | ↑ 54.29% |
Total Liabilities | 8.2M | ↑ 248.85% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 10.6M | ↓ 16.17% |
Total Liabilities | 7.5M | ↓ 8.61% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -4.4M | ↑ 69.1% |
Investing Cash Flow | 3.3M | ↓ 509.85% |
Financing Cash Flow | -2.3M | ↓ 63.04% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.8M | ↑ 31.21% |
Investing Cash Flow | 7.7M | ↑ 131.57% |
Financing Cash Flow | 550.2K | ↓ 123.93% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.6M | ↑ 13.69% |
Investing Cash Flow | 22.1M | ↑ 187.02% |
Financing Cash Flow | 255.5K | ↓ 53.57% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.3M | ↑ 71.53% |
Investing Cash Flow | 5.2M | ↓ 76.4% |
Financing Cash Flow | 1.2M | ↑ 381.49% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -8.1M | ↓ 28.32% |
Investing Cash Flow | -2.4M | ↓ 145.37% |
Financing Cash Flow | 543.6K | ↓ 55.81% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.2M | ↑ 30.04% |
Investing Cash Flow | 2.8M | ↑ 347.83% |
Financing Cash Flow | 0.0 | ↓ 100.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.7M | ↓ 24.34% |
Investing Cash Flow | 1.1M | ↓ 59.49% |
Financing Cash Flow | 0.0 | - |
Sell
Neutral
Buy
Dyadic International Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Dyadic International Inc | -6.67% | -9.35% | -31.15% | -79.0% | -76.84% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Dyadic International Inc | NA | NA | 0.0 | -0.26 | -1.27 | -0.46 | NA | 0.11 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Dyadic International Inc | Buy | $38.7M | -76.84% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Dyadic International Inc
Revenue is up for the last 2 quarters, 334.61K → 385.89K (in $), with an average increase of 13.3% per quarter
Netprofit is down for the last 2 quarters, -2.00M → -2.04M (in $), with an average decrease of 1.8% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 68.2%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 148.2%
Bandera Partners LLC
Chapin Davis Inc
Vanguard Group Inc
Northeast Financial Consultants, Inc
BlackRock Inc
Geode Capital Management, LLC
dyadic international, inc. (otcqx: dyai) - we are a global biotechnology company focused on further improving and leveraging the patented and proprietary c1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system - but most importantly to save lives.
Organization | Dyadic International Inc |
Employees | 7 |
CEO | Mr. Mark A. Emalfarb |
Industry | Biotechnology |
A Spac I Acquisition Corp
$1.26
-0.79%
Keyarch Acquisition Corp
$1.26
-0.79%
Connexa Sports Technologies Inc
$1.26
-0.79%
Us Value Etf
$1.26
-0.79%
First Wave Biopharma Inc
$1.26
-0.79%
Global X Msci Next Emerging
$1.26
-0.79%
Fat Projects Acquisition Corp
$1.26
-0.79%
Capital Link Global Fintech
$1.26
-0.79%
Applied Uv Inc
$1.26
-0.79%